BOSTON, March 30 /PRNewswire-FirstCall/ -- ViaCell, Inc. , announced today that Marc D. Beer, President and CEO, is scheduled to give a corporate update at the Lehman Brothers Eighth Annual Healthcare Conference. The presentation is scheduled to occur on Thursday, March 31, 2005 at 2:00 p.m. Eastern Time at the Loews Miami Beach Hotel. Interested parties may access the live audio webcast of the presentation and replay it by visiting the ViaCell website at http://www.viacellinc.com/. The webcast replay of the presentation will be archived on ViaCell's website until April 14, 2005.
About ViaCell
ViaCell, Inc. is a clinical-stage biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company is developing a pipeline of proprietary product candidates intended to address cancer, cardiac disease, diabetes and infertility. ViaCell's portfolio of proprietary technologies includes Selective Amplification technology and USSCs. The Company's lead cord-blood derived stem cell therapy product candidate, CB001, is currently in a Phase I clinical trial. ViaCell also offers expecting families the option of preserving their baby's cord blood stem cells through its Viacord business.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 and it is the Company's intent that such statements be protected by the safe harbor created thereby. Examples of such statements include, but are not limited to, statements relating to: projected revenue growth, the filing of an IND and subsequent advancement of the USSC program into Phase I clinical studies, completion of and favorable results from the CB001 Phase I clinical trial and advancement into Phase II trials, the potential benefits of the Company's product candidates and the potential marketing approval and launch of the Viacyte product candidate. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to: adverse effects on revenues related to litigation, competition and public perception regarding the Company's product; difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates that could slow or prevent product approval or market acceptance; the Company's ability to obtain additional financing if necessary to support development and commercialization activities or unanticipated research and development cost; and uncertainties inherent in anticipating the results of pre-clinical and clinical studies. For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission, including the matters discussed under the heading "Risk Factors" in the Company's prospectus filed via EDGAR with the Commission on January 21, 2005. ViaCell does not undertake any obligation to update forward-looking statements.
Corporate Contact: Investors: Stephen G. Dance Jonathan Nugent (jnugent@burnsmc.com) ViaCell, Inc. Media: (617) 914-3535 Justin Jackson (jjackson@burnsmc.com) sdance@viacellinc.com Burns McClellan, Inc. (212) 213-0006
ViaCell, Inc.CONTACT: Stephen G. Dance of ViaCell, Inc., +1-617-914-3535,sdance@viacellinc.com; or Jonathan Nugent, jnugent@burnsmc.com, or JustinJackson, jjackson@burnsmc.com both of Burns McClellan, Inc., +1-212-213-0006
Web site: http://www.viacord.com/
